Table S2.
Dropout analyses
| Baseline characteristics | 48-month follow-up data available?
|
||
|---|---|---|---|
| Yes (n=137) | No (n=114) | p-value | |
| Female gender, n (%) | 109/137 (79.6%) | 99/114 (86.8%) | 0.1275 |
| Age (years) | 50.96±11.28 | 48.02±12.01 | 0.0413 |
| Duration of rheumatoid arthritis (months) | 14.44±9.76 | 12.23±8.93 | 0.0813 |
| Rheumatoid factor (IU/mL) | 148.22±217.62 | 188.35±276.85 | 0.6467 |
| Rheumatoid factor positive (≥20 IU/mL), n (%) | 112/129 (86.8%) | 92/109 (83.6%) | 0.4875 |
| C-reactive protein (mg/dL) | 2.77±4.74 | 2.45±3.03 | 0.6224 |
| Joint tenderness (Ritchie Index, 0–78) | 13.14±8.02 | 13.34±9.77 | 0.7506 |
| Number of swollen joints | 14.11±7.90 | 15.25±7.64 | 0.2469 |
| Hanover Functional Ability Questionnaire | 17.75±4.44 | 16.92±5.04 | 0.2597 |
| Radiological signs of joint destruction (Ratingen Score) | 2.12±4.05 | 2.52±4.58 | 0.5744 |
| Erosive arthritis with Ratingen Score ≥1, n (%) | 45/137 (32.8%) | 35/104 (33.7%) | 0.8954 |
| Corticosteroid use, n (%) | 54/137 (39.4%) | 38/114 (33.3%) | 0.3194 |
Note: Data are presented as mean ± SD, unless otherwise stated.